| Previous Close | 83.04 |
| Open | 83.45 |
| Bid | 82.00 x 100 |
| Ask | 85.79 x 100 |
| Day's Range | 82.90 - 83.92 |
| 52 Week Range | 64.18 - 86.72 |
| Volume | 3,035,321 |
| Avg. Volume | 3,883,829 |
| Market Cap | 87.42B |
| Beta | 0.18 |
| PE Ratio (TTM) | 40.18 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.47%) |
| Ex-Dividend Date | 2017-05-11 |
| 1y Target Est | N/A |
- Motley Fool•yesterday
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
Find out which of these pharmaceutical stocks is the best pick right now.
- Investor's Business Daily•yesterday
This Biotech Crashed 28% Despite Positive Migraine Drug Tests
Alder stock dove to a nearly three-year low Tuesday despite strong data in a Phase 3 migraine trial, making it competitive with Lilly, Amgen and Teva.
- Barrons.com•yesterday
[$$] Merck Cholesterol Drug Could Help Unlock Value
In the last decade, no fewer than three major pharmaceutical companies have suffered defeat trying to bring a new class of cholesterol-lowering medication to market.s Much to the surprise of investors, Merck & Co. (MRK) could succeed where Pfizer (PFE), Roche (RHHBY) and Eli Lilly & Co. (LLY) have all failed. Merck has yet to decide if it will seek Food and Drug Administration approval, a sign to some that the company isn’t sure if the study data, though positive, are strong enough to ensure regulatory approval. Thanks to the growing success of Merck’s immunotherapy cancer drug Keytruda, the shares have gained 19% in the past year to near a 52-week high of $66.80.
